Company profile: Trace Genomics
1.1 - Company Overview
Company description
- Provider of soil health and microbiome analysis using next-generation sequencing to deliver genetic insights into soil for optimizing agricultural practices, crop yield, and sustainability. Offerings include TraceCOMPLETE (pathogen, fertility, and soil management insights), TraceCARBON (soil carbon stocks), metagenomics, hi-definition DNA and chemical soil analysis, and a farm data privacy and protection policy.
Products and services
- Metagenomics: A next-generation sequencing-based method that sequences all DNA in a soil sample to identify microbes and supply a complete picture of the soil’s biological environment
- TraceCOMPLETE: A laboratory-grade soil analysis system integrating biology and chemistry tools to deliver pathogen detection, fertility assessment, and actionable soil management insights using advanced genetic analysis
- TraceCARBON: A time-series, quantitative soil carbon measurement product that tracks carbon stocks and sequestration over time to aid understanding and reduction of an operation’s carbon footprint
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Trace Genomics
GenVault
HQ: United States
Website
- Description: Provider of sample management solutions for disease diagnosis, research, identification and criminal investigations, offering secure, GxP-compliant biorepository storage for over 60,000,000 samples (ambient to cryogenic), specialized transport and lab relocation with full chain-of-custody and GxP/USDOT compliance, and end-to-end bioinventory support—accession, monitoring, tracking, reporting and disposal—via a secure online portal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVault company profile →
Alsachim
HQ: France
Website
- Description: Provider of contract research and development services to customers around the world, stable isotope-labeled compounds for pharmaceuticals, environmental studies, and clinical diagnostics, and labeled internal and reference standards for LC-MS/MS analysis to ensure accurate quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alsachim company profile →
ATDBio
HQ: United Kingdom
Website
- Description: Provider of specialized, large-scale DNA and RNA oligonucleotide production and innovation expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ATDBio company profile →
Spatial Transcriptomics
HQ: Sweden
Website
- Description: Provider of technology to perform RNA sequencing in 2D.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spatial Transcriptomics company profile →
Durect
HQ: United States
Website
- Description: Provider of specialty pharmaceutical drug development focused on pain and chronic diseases, with late-stage programs including REMOXY, POSIDUR, ELADUR, and TRANSDUR-Sufentanil, leveraging proprietary oral, transdermal and injectable depot delivery technologies to enable new indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durect company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Trace Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Trace Genomics
2.2 - Growth funds investing in similar companies to Trace Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Trace Genomics
4.2 - Public trading comparable groups for Trace Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →